Assistant Professor of Medicine
Member of the Duke Clinical Research Institute
Member of the Duke Cancer Institute
Email address
david.leiman@duke.edu
Education and Training
- Fellowship in Gastroenterology and Hepatology, Medicine, University of Pennsylvania, School of Medicine, 2012 - 2015
- Internal Medicine Residency, Medicine, University of Pennsylvania, School of Medicine, 2009 - 2012
- M.D., Vanderbilt University, School of Medicine, 2009
Grants
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Who Have an Inadequate R
- A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studyto Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Duodenitis who have an Inadequate Response with, Lost Response to, or
- A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and have Eosinophilic Gastritis and/or Eosinophilic Duodenitis
- A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole
- A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study toEvaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonop
- PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer
- Eosinophilic Esophagitis (EoE)